Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab With or Without Chemotherapy or Lenvatinib in First-Line Treatment of Advanced Biliary Tract Cancer
NCT06230471Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib in biliary tract cancer (BTC) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective Response Rate at 6 months. Started Jan 2023; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06230471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06230471.